ClinicalTrials.gg
RecruitingNCT05608681RESOLVEUpdated Nov 17, 2026

A Trial to Evaluate EP-104GI in Adults With Eosinophilic Esophagitis (EoE).

A Phase 1/2 interventional study of EP-104GI and Matching vehicle control in Eosinophilic Esophagitis, sponsored by Eupraxia Pharmaceuticals Inc.. Recruiting at 33 sites in 6 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Eupraxia Pharmaceuticals Inc. · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2023; still recruiting 3 years 7 months later.
Updated Nov 17, 2026Site recruiting status changed11 sites added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
117
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Eosinophilic Esophagitis with a site in Australia — 1 open to participants now, 3 under way, 1 of them phase 3. Eosinophilic Esophagitis · Australia.

Planned enrollment
8th of 11
117 · median 184
Started
2023
with 1 other
Phase 1/2
Only one
of the 11
Registered
9th of 11
by date
Lead sponsor
1 of 11
Eupraxia Pharmaceuticals Inc.

Among the 11 studies in Eosinophilic Esophagitis with a site in Australia, this one is the 8th largest by planned enrollment, is one of 2 that started in 2023, is the only one in phase 1/2, and was the 9th registered.

Eosinophilic Esophagitis

235 studies on the registry are indexed under Eosinophilic Esophagitis; 53 are open to participants now.

Browse Eosinophilic Esophagitis studies →

Open to participants now

1 of the 11 studies in Eosinophilic Esophagitis with a site in Australia is open now.

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 43 Eosinophilic Esophagitis studies recruiting now, 13 (30%) set no upper age limit and 27 (63%) stop at 75 or younger; 27 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Eosinophilic Esophagitis with a site in Australia, or all of them as a file.
02

Study summary

A Phase 1b/2 study to explore the safety, efficacy and pharmacokinetics of EP-104GI in adults with eosinophilic esophagitis (EoE). Endoscopic and histologic assessments will also be evaluated to understand the local effects of EP-104GI on eosinophilic EoE disease activity. Approximately 27 to 33 participants will be enrolled in dose escalation: 3-6 participants per dose cohort. The number of participants enrolled in escalation will depend on the number of dose escalation cohorts evaluated, and dose cohorts needing to be expanded. An additional 10-24 participants will be enrolled in 1 or 2 cohorts of 10-12 participants each at tolerable dose regimen(s) selected based on the accumulated clinical data to identify the recommended phase 2 dose(s) (RP2D). In the Phase 2 randomized dose optimization portion of the study, approximately 120 subjects will be randomized to Dose A (120 mg total dose), Dose B (160 mg total dose), or matching vehicle control, with an overall assignment ratio of 1:1:1. The total number of participants in both portions of the study will be approximately 160. The study involves 8-10 site visits spread over approximately 52 weeks. Participants in an extended PK sub study will have up to 4 additional visits, to a maximum of 108 weeks post-dose. The participants will either receive the active study drug (EP-104GI) or matching vehicle control. Matching vehicle control will be used only in randomized dose optimization portion of the study. Participants randomized to receive vehicle control may receive EP-104GI (Dose A or Dose B) following the completion of Week 24 providing they meet eligibility criteria for crossover to EP-104GI. Participants randomized to receive EP-104GI on Day 0 will not receive EP-104GI or vehicle control at Week 24. The study drug or matching vehicle control will be administered by qualified personnel during an esophagogastroduodenoscopy (EGD) procedure at the Baseline/Dosing visit. Safety will be assessed throughout the study. Blood and urine samples will be collected at site visits for laboratory assessments and to measure plasma levels of EP-104GI. Participants will complete questionnaires to assess symptoms of dysphagia and odynophagia and will undergo 3-5 EGDs with esophageal biopsies at the Baseline, Week 4 (dose escalation phase only), Week 12, Week 24 (randomized dose optimization phase only), Week 26, and Week 52 (randomized dose optimization phase only).

03

Conditions studied

  • Eosinophilic Esophagitis
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Symptomatic EoE;
  • For women of , a negative pregnancy test and willing to use a highly effective method of until end of study;
  • Willing and able to adhere to study-related procedures and visit schedule;
  • Willing and able to provide .

Criteria for crossover to EP 104GI from vehicle control (randomized dose optimization portion):

  1. Has completed the randomized dose optimization portion of the trial to Week 24, inclusive
  2. Without safety concerns for receiving EP 104GI ie, does not meet exclusion criteria or have other safety issue

Exclusion criteria

Exclusion Criteria:

  • Concomitant esophageal disease, relevant GI disease, or any condition, history, or laboratory abnormality that might interfere with the study;
  • Oral or esophageal mucosal infection of any type (bacterial, viral, or fungal);
  • Oropharyngeal or dental conditions that prevents normal eating;
  • Severe esophageal motility disorders other than EoE;
  • to or factors that substantially increase risks associated with EGD or , or narrowing of the esophagus that precludes EGD with a standard 9-10 mm endoscope, stricture requiring dilation within 8 weeks prior to Screening, or the need for dilation prior to EGD at Baseline;
  • Any condition for which the use of is contraindicated (Participants with well controlled non-insulin dependent diabetes are permitted);
  • Active or quiescent systemic fungal, bacterial, viral, or parasitic infections, or ocular herpes simplex. Or recent use of IV or oral antibiotics;
  • , or intolerance to corticosteroids, or to any of the ingredients in the medicinal product, including carboxymethyl cellulose, and polysorbate 80, or to the ingredients in Synacthen / cosyntropin (used in the ACTH stimulation test);
  • Recent use of disallowed medications, or unwillingness to not use disallowed medications during the study;
  • Recent initiation of a elimination or elemental diet (dietary therapy must remain stable throughout the study);
  • Morning serum cortisol level ≤ 5 μg/dL (138 nmol/L);
  • abnormal laboratory values;
  • Recent or currently planned participation in another interventional trial ;
  • Previous participation in this study and had received study treatment;
  • Females who are pregnant, breastfeeding, or planning to become pregnant during the study;
  • or history of malignancy within prior 5 years, except for treated or excised non- BCC, SCC of the skin, or cervical carcinoma in situ;
  • History of alcohol or drug abuse;
  • Any other reason, that, in the Investigator's opinion, unfavorably alters participant risk, confounds results, or prevents the participant from complying with study requirements.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
117 participants (estimated)

Study arms

  • Experimental
    EP-104GI 4 mg

    4 submucosal injections of EP-104GI administered during an EGD procedure at the Baseline/Dosing visit.

    Drug: EP-104GI

  • Experimental
    EP-104GI 8 mg

    8 submucosal injections of EP-104GI administered during an EGD procedure at the Baseline/Dosing visit.

    Drug: EP-104GI

  • Experimental
    EP-104GI 20 mg

    8 submucosal injections of EP-104GI administered during an EGD procedure at the Baseline/Dosing visit.

    Drug: EP-104GI

  • Experimental
    EP-104GI 30 mg

    12 submucosal injections of EP-104GI administered during an EGD procedure at the Baseline/Dosing visit.

    Drug: EP-104GI

  • Experimental
    EP-104GI 48 mg

    12 submucosal injections of EP-104GI administered during an EGD procedure at the Baseline/Dosing visit.

    Drug: EP-104GI

  • Experimental
    EP-104GI 64 mg

    16 submucosal injections of EP-104GI administered during an EGD procedure at the Baseline/Dosing visit.

    Drug: EP-104GI

  • Experimental
    EP-104GI 80 mg

    20 submucosal injections of EP-104GI administered during an EGD procedure at the Baseline/Dosing visit.

    Drug: EP-104GI

  • Experimental
    EP-104GI 96 mg

    16 submucosal injections of EP-104GI administered during an EGD procedure at the Baseline/Dosing visit.

    Drug: EP-104GI

  • Experimental
    EP-104GI 120 mg

    20 submucosal injections of EP-104GI administered during an EGD procedure at the Baseline/Dosing visit.

    Drug: EP-104GI

  • Placebo comparator
    EP-104GI Dose A or matching vehicle control

    20 submucosal injections of EP-104GI administered during an EGD procedure at the Baseline/Dosing visit.

    Drug: EP-104GI · Other: Matching vehicle control

  • Experimental
    EP-104GI 160 mg

    20 submucosal injections of EP-104GI administered during an EGD procedure at the Baseline/Dosing visit.

    Drug: EP-104GI

  • Placebo comparator
    EP-104GI Dose B or matching vehicle control

    20 submucosal injections of EP-104GI administered during an EGD procedure at the Baseline/Dosing visit.

    Drug: EP-104GI · Other: Matching vehicle control

Interventions

  • DrugEP-104GI

    Extended-release fluticasone propionate \[FP\] for injectable suspension for gastrointestinal administration, Powder suspended in vehicle

  • OtherMatching vehicle control

    A sterile liquid containing sterile water and excipients necessary to prepare a uniform suspension of the powder.

06

What researchers measure

Primary outcomes

  1. Dose Escalation- Incidence of treatment emergent adverse events (TEAEs)

    TEAEs will be summarized by dose/cohort

    Time frame: 52 weeks

  2. Dose Escalation- Severity of treatment emergent adverse events (TEAEs)

    TEAEs will be summarized by dose/cohort and severity (mild, moderate, severe).

    Time frame: 52 weeks

  3. Dose Escalation- Change from baseline in morning serum cortisol levels

    Cortisol will be will be summarized by dose/cohort and over time and compared to pre-dose values. A prolonged and clinically significant reduction in cortisol may indicate adrenal insufficiency.

    Time frame: 52 weeks

  4. Dose Escalation- Plasma concentrations of fluticasone propionate

    Plasma concentrations of fluticasone propionate over time will be used to calculate PK parameters for each dose/cohort.

    Time frame: 108 weeks

  5. Dose Escalation- Change from baseline in physical examination results, BMI and weight change.

    Physical examination results, BMI and weight will be summarized by dose/cohort and over time and compared to pre-dose values.

    Time frame: 12 weeks

  6. Randomised Dose Optimization- Change from baseline in EoEHSS grade and stage scored in 3 regions of the esophagus within the injection area (proximal, mid, distal)

    The EoEHSS scores the stage and grade of 8 histologic items: eosinophil inflammation, basal zone hyperplasia, dilated intercellular spaces, eosinophil abscesses, surface layering, surface epithelial alteration, dyskeratotic epithelial cells and lamina propria fibrosis), on separate 4-point Likert scales. A composite EoEHSS grade and stage scores are calculated by summing the individual grade and stage items and dividing by the maximum score for evaluated items (range, 0-1). A lower score indicates improvement.

    Time frame: 24 weeks

Secondary outcomes

  1. Dose Escalation- Peak eosinophil count (PEC)

    Biopsy specimens will be used to evaluate peak eosinophil counts (PEC). A higher number of eosinophils indicates more severe histological disease.

    Time frame: 36 weeks

  2. Dose Escalation- Change from baseline in the Straumann Dysphagia Index (SDI) score

    The SDI is a patient-reported outcome measure of dysphagia with a 7-day recall period. The SDI assesses the frequency and intensity of dysphagia on two separate 5-point and 6-point scales. Total SDI scores are calculated by adding the two sub-scores (range, 0-9), with a higher total score indicating more severe dysphagia.

    Time frame: 52 weeks

  3. Dose Escalation- Change from baseline in dysphagia measured on an 11 point Likert scale

    The participant will assess the severity of their dysphagia symptoms (troubles to swallow) over the previous 7-days using an 11-point Likert scale where 0 = no trouble and 10 = most severe trouble swallowing.

    Time frame: 52 weeks

  4. Dose Escalation- Change from baseline in the EoE Endoscopic Reference Score (EREFS)

    Endoscopic Reference Score (EREFS) scoring system is used to determine the severity of 5 endoscopic findings: edema, rings, exudates, furrows, and strictures. The total EREFS is calculated by summing the grades of the 5 individual endoscopic items (range, 0 to 9), with higher scores indicating more severe endoscopic disease.

    Time frame: 36 weeks

  5. Dose Escalation- Change from baseline in odynophagia measured on an 11 point Likert scale

    The participant will assess the severity of their pain during swallowing over the previous 7 days using an 11 point Likert scale where 0 = no pain and 10 = most severe pain during swallowing.

    Time frame: 52 weeks

  6. Dose Escalation- Change from baseline in EoE Histology Scoring System (EoEHSS) score

    The EoEHSS scores the stage and grade of 8 histologic items: eosinophil inflammation, basal zone hyperplasia, dilated intercellular spaces, eosinophil abscesses, surface layering, surface epithelial alteration, dyskeratotic epithelial cells and lamina propria fibrosis), on separate 4-point Likert scales. A composite EoEHSS grade and stage scores are calculated by summing the individual grade and stage items and dividing by the maximum score for evaluated items (range, 0-1). A lower score indicates improvement.

    Time frame: 36 weeks

  7. Randomised Dose Optimization- Change from baseline in the Straumann Dysphagia Index (SDI) score

    The SDI is a patient-reported outcome measure of dysphagia with a 7-day recall period. The SDI assesses the frequency and intensity of dysphagia on two separate 5-point and 6-point scales. Total SDI scores are calculated by adding the two sub-scores (range, 0-9), with a higher total score indicating more severe dysphagia.

    Time frame: 52 weeks

  8. Randomised Dose Optimization- Change from baseline in the Dysphagia symptom questionnaire (DSQ) v4.0 and "Dysphagia days"

    The DSQ is assessed daily over a period of 14 days and comprises four questions; one question on whether the participant has eaten solid food and three questions on the presence and severity of EoE dysphagia."Dysphagia Days" is defined as the number of days with a yes answer to the following question: During any meal today, did food go down slowly or get stuck in your throat or chest?

    Time frame: 52 weeks

  9. Randomised Dose Optimization- Change from baseline in the Eosinophilic Esophagitis Impact Questionnaire (EoE IQ)

    The EoE-IQ is a validated PRO instrument consisting of 11 questions assessing the impact of EoE on health related quality of life.

    Time frame: 52 weeks

  10. Randomised Dose Optimization- Change from baseline in the Patient Global Impression of Change (PGIC)

    The PGIC reflects a participant's belief about the efficacy of treatment on a 7 point scale rating on a 4 point scale.

    Time frame: 52 weeks

  11. Randomised Dose Optimization- Change from baseline in the Patient Global Impression of Severity (PGIS)

    The PGIS reflects a participant's belief about the efficacy of treatment based on severity ranging from none to very severe.

    Time frame: 52 weeks

  12. Randomised Dose Optimization- Change from baseline in peak eosinophil count (PEC)

    Biopsy specimens will be used to evaluate peak eosinophil counts (PEC). A higher number of eosinophils indicates more severe histological disease.

    Time frame: 52 weeks

  13. Randomised Dose Optimization- Change from baseline in the EoE Endoscopic Reference Score (EREFS) in 3 regions of the esophagus within the injection area (proximal, mid, distal)

    Endoscopic Reference Score (EREFS) scoring system is used to determine the severity of 5 endoscopic findings: edema, rings, exudates, furrows, and strictures. The total EREFS is calculated by summing the grades of the 5 individual endoscopic items (range, 0 to 9), with higher scores indicating more severe endoscopic disease.

    Time frame: 52 weeks

  14. Randomised Dose Optimization- Change in endoscopist's global impression of severity

    The PGIC reflects a participant's belief about the efficacy of treatment on a 7 point scale rating overall improvement; the PGIS reflects a participant's belief about the severity of their symptoms on a 4 point scale

    Time frame: 52 weeks

  15. Randomised Dose Optimization- Change from baseline in EoE Histology Scoring System (EoEHSS) score in 3 regions of the esophagus within the injection area (proximal, mid, distal), excluding Week 24 as this is the primary endpoint

    The EoEHSS scores the stage and grade of 8 histologic items: eosinophil inflammation, basal zone hyperplasia, dilated intercellular spaces, eosinophil abscesses, surface layering, surface epithelial alteration, dyskeratotic epithelial cells and lamina propria fibrosis), on separate 4-point Likert scales. A composite EoEHSS grade and stage scores are calculated by summing the individual grade and stage items and dividing by the maximum score for evaluated items (range, 0-1). A lower score indicates improvement.

    Time frame: 52 weeks

  16. Randomised Dose Optimization- Change from baseline in morning serum cortisol levels

    Cortisol will be will be summarized by dose/cohort and over time and compared to pre-dose values. A prolonged and clinically significant reduction in cortisol may indicate adrenal insufficiency.

    Time frame: 52 weeks

  17. Randomised Dose Optimization- Change from baseline in vital signs (temperature, blood pressure, pulse, and respiratory rate) results

    Vital signs (temperature, blood pressure, pulse, and respiratory rate) results will be summarized by dose/cohort and over time and compared to pre-dose values.

    Time frame: 52 weeks

  18. Randomised Dose Optimization- Change from baseline in physical examination results, BMI and weight change.

    Physical examination results, BMI and weight will be summarized by dose/cohort and over time and compared to pre-dose values.

    Time frame: 52 weeks

  19. Randomised Dose Optimization- Plasma concentrations of fluticasone propionate

    Plasma concentrations of fluticasone propionate over time will be used to calculate PK parameters for each dose/cohort.

    Time frame: 108 weeks

07

Study locations

26 of 33 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2023 (actual). Primary completion is estimated for Dec 2026, 45 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 19, 2022
First posted
Nov 8, 2022
StartActual
Mar 31, 2023
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
11 sites added, 1 site removed. 4 sites changed recruiting status (4 now active, not recruiting)
Show 4 sites
  • Mater Hospital Brisbane · Brisbane, AustraliaRecruiting→Active, not recruiting
  • Erasmus University Medical Center · Holland, NetherlandsRecruiting→Active, not recruiting
  • Waikato Hospital · Hamilton, New ZealandRecruiting→Active, not recruiting
  • Royal Liverpool University Hospital · Liverpool, United KingdomRecruiting→Active, not recruiting
Show 11 added (6 Canada, 3 Australia, 2 United Kingdom)
  • Lyell McEwin Hospital · Elizabeth Vale, Australia
  • Tennyson Centre Day Hospital · Kurralta Park, Australia
  • St John of God Midland · Midland, Australia
  • South Edmonton Gastroenterology Research Clinic · Edmonton, Canada
  • Brampton Gastroenterology Research Group Inc. · Brampton, Canada
  • Charlton Digestive Disease Centre · Hamilton, Canada
  • McMaster University · Hamilton, Canada
  • West GTA Research Inc. · Mississauga, Canada
  • TIDHI Innovation Inc. · Toronto, Canada
  • Cambridge University Hospitals NHS Foundation Trust · Cambridge, United Kingdom
  • Belfast Trust · Belfast, United Kingdom
Show 1 removed
  • UoA - South Edmonton Gastroenterology Research Clinic · Edmonton, Canada
Nov 17, 2026
Site contacts
Changed at 6 sites. See the sites
Show 6 sites
  • Mater Hospital Brisbane · Brisbane, AustraliaContact removed S•••@mater.org.auContact removed (no phone or email listed)
  • University of Calgary · Calgary, CanadaContact s•••@ualberta.ca→e•••@ucalgary.ca
  • Erasmus University Medical Center · Holland, NetherlandsContact removed m•••@erasmusmc.nlContact removed (no phone or email listed)
  • Aotearoa Clinical Trials · Papatoetoe, New ZealandContact I•••@aotearoatrials.nz→e•••@aotearoatrials.nz
  • Waikato Hospital · Hamilton, New ZealandContact removed h•••@waikatodhb.health.nzContact removed (no phone or email listed)
  • Royal Liverpool University Hospital · Liverpool, United KingdomContact removed c•••@liverpoolft.nhs.ukContact removed (no phone or email listed)
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    11 sites added, 1 site removed. 4 sites changed recruiting status (4 now active, not recruiting)
    Show 4 sites
    • Mater Hospital Brisbane · Brisbane, AustraliaRecruiting→Active, not recruiting
    • Erasmus University Medical Center · Holland, NetherlandsRecruiting→Active, not recruiting
    • Waikato Hospital · Hamilton, New ZealandRecruiting→Active, not recruiting
    • Royal Liverpool University Hospital · Liverpool, United KingdomRecruiting→Active, not recruiting
    Show 11 added (6 Canada, 3 Australia, 2 United Kingdom)
    • Lyell McEwin Hospital · Elizabeth Vale, Australia
    • Tennyson Centre Day Hospital · Kurralta Park, Australia
    • St John of God Midland · Midland, Australia
    • South Edmonton Gastroenterology Research Clinic · Edmonton, Canada
    • Brampton Gastroenterology Research Group Inc. · Brampton, Canada
    • Charlton Digestive Disease Centre · Hamilton, Canada
    • McMaster University · Hamilton, Canada
    • West GTA Research Inc. · Mississauga, Canada
    • TIDHI Innovation Inc. · Toronto, Canada
    • Cambridge University Hospitals NHS Foundation Trust · Cambridge, United Kingdom
    • Belfast Trust · Belfast, United Kingdom
    Show 1 removed
    • UoA - South Edmonton Gastroenterology Research Clinic · Edmonton, Canada
    Site contacts Changed at 6 sites. See the sites
    Show 6 sites
    • Mater Hospital Brisbane · Brisbane, AustraliaContact removed S•••@mater.org.auContact removed (no phone or email listed)
    • University of Calgary · Calgary, CanadaContact s•••@ualberta.ca→e•••@ucalgary.ca
    • Erasmus University Medical Center · Holland, NetherlandsContact removed m•••@erasmusmc.nlContact removed (no phone or email listed)
    • Aotearoa Clinical Trials · Papatoetoe, New ZealandContact I•••@aotearoatrials.nz→e•••@aotearoatrials.nz
    • Waikato Hospital · Hamilton, New ZealandContact removed h•••@waikatodhb.health.nzContact removed (no phone or email listed)
    • Royal Liverpool University Hospital · Liverpool, United KingdomContact removed c•••@liverpoolft.nhs.ukContact removed (no phone or email listed)

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05608681
Lead sponsor
Eupraxia Pharmaceuticals Inc.
Responsible party
Sponsor
First posted
Nov 8, 2022
Start date
Mar 31, 2023
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Nov 17, 2026

Study contacts

Pranali Ravikumar, MS
Contact
pravikumar@eupraxiapharma.com
647-895-3016
Jeymi Tambiah, MD
study director · Eupraxia Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion